Skip to main content Skip to section navigation Skip to footer
Achieve Life Sciences, Inc. IR Overview
Achieve Life Sciences Logo
  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Careers
  • Products
    • Phase 3 ORCA-3 Trial
    • Phase 3 ORCA-2 Trial
    • Phase 2 ORCA-1 Trial
    • Phase 2 ORCA-V1 Trial
    • Expanded Access Policy
    • Resources
  • Investors
  • News
  • Contact

IR Calendar

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Information
    • Overview
    • Management Team
    • Contacts
  • Financial Information
    • Overview
    • Financial Results
  • Stock Data
    • Quote and Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Whistleblower Information

  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts

Second Quarter 2025 Earnings Conference Call

Aug 7, 2025 8:30 am EDT
Earnings ReleaseHTML
Earnings WebcastAudio
10-QHTML XBRL Zip
  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap
  • US Headquarters
  • 22722 29th Dr SE,
    Suite 100
  • Bothell, WA 98021
  • Phone: (425) 686-1500
  • Vancouver Office
  • 1040 W Georgia Street,
    Suite 1030
  • Vancouver, BC V6E 4H1

About

  • About
  • Management Team
  • Board of Directors
  • Scientific Advisors
  • Careers

For Investors

  • Investors
  • News
  • Corporate Governance
  • Financial Information
  • SEC Filings

Recent News

May 19, 2026
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
More News

© Copyright 2026 | Achieve Life Sciences, Inc., Inc. All Rights Reserved

  • Privacy Policy
  • Disclaimer
  • Contact
  • References
  • twitter
  • linkedin